BioCentury | May 12, 2014
Company News

J&J, WHO infectious news

...and funding agencies, foundations and other private groups. Sirturo, a diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
...and funding agencies, foundations and other private groups. Sirturo, a diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Mar 10, 2014
Clinical News

Sirturo bedaquiline regulatory update

...said the trial is slated to start this year. The diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Dec 23, 2013
Clinical News

Sirturo bedaquiline regulatory update

...exclusive, royalty-free, worldwide license to develop the product - a diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Jul 1, 2013
Clinical News

Bedaquiline regulatory update

...therapy when other alternatives are not available. Sirturo is a diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Jan 7, 2013
Clinical News

Sirturo bedaquiline regulatory update

...said it will disclose the price when it launches the diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Jan 3, 2013
Top Story

FDA approves bedaquiline

...said it will disclose the price when it launches the diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Dec 3, 2012
Clinical News

Sirturo bedaquiline regulatory update

...proposed a REMS that includes a restricted distribution system. The diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Nov 29, 2012
Company News

FDA panel backs accelerated approval of bedaquiline

..."favorable treatment outcome," or how this will be measured. The diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Nov 27, 2012
Company News

FDA releases bedaquiline briefing docs

...with a Dec. 29 PDUFA date. An MAA for the diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
BioCentury | Oct 1, 2012
Clinical News

Bedaquiline regulatory update

...to EMA for bedaquiline for the indication. Bedaquiline is a diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase...
Items per page:
1 - 10 of 23